Next Article in Journal
Chitosan-Alginate Biocomposite Containing Fucoidan for Bone Tissue Engineering
Next Article in Special Issue
Marine Low Molecular Weight Natural Products as Potential Cancer Preventive Compounds
Previous Article in Journal / Special Issue
Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development
Mar. Drugs 2014, 12(1), 279-299; doi:10.3390/md12010279
Article

The Marine Fungal Metabolite, AD0157, Inhibits Angiogenesis by Targeting the Akt Signaling Pathway

1,2,3
, 4
, 4
, 1,2
 and 1,2,*
Received: 12 November 2013; in revised form: 26 December 2013 / Accepted: 27 December 2013 / Published: 16 January 2014
(This article belongs to the Special Issue Marine Compounds and Cancer)
View Full-Text   |   Download PDF [796 KB, uploaded 16 January 2014]   |   Browse Figures
Abstract: In the course of a screening program for the inhibitors of angiogenesis from marine sources, AD0157, a pyrrolidinedione fungal metabolite, was selected for its angiosupressive properties. AD0157 inhibited the growth of endothelial and tumor cells in culture in the micromolar range. Our results show that subtoxic doses of this compound inhibit certain functions of endothelial cells, namely, differentiation, migration and proteolytic capability. Inhibition of the mentioned essential steps of in vitro angiogenesis is in agreement with the observed antiangiogenic activity, substantiated by using two in vivo angiogenesis models, the chorioallantoic membrane and the zebrafish embryo neovascularization assays, and by the ex vivo mouse aortic ring assay. Our data indicate that AD0157 induces apoptosis in endothelial cells through chromatin condensation, DNA fragmentation, increases in the subG1 peak and caspase activation. The data shown here altogether indicate for the first time that AD0157 displays antiangiogenic effects, both in vitro and in vivo, that are exerted partly by targeting the Akt signaling pathway in activated endothelial cells. The fact that these effects are carried out at lower concentrations than those required for other inhibitors of angiogenesis makes AD0157 a new promising drug candidate for further evaluation in the treatment of cancer and other angiogenesis-related pathologies.
Keywords: AD0157; angiogenesis; cancer; apoptosis; marine drug; pyrrolidinedione AD0157; angiogenesis; cancer; apoptosis; marine drug; pyrrolidinedione
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

García-Caballero, M.; Cañedo, L.; Fernández-Medarde, A.; Medina, M.Á.; Quesada, A.R. The Marine Fungal Metabolite, AD0157, Inhibits Angiogenesis by Targeting the Akt Signaling Pathway. Mar. Drugs 2014, 12, 279-299.

AMA Style

García-Caballero M, Cañedo L, Fernández-Medarde A, Medina MÁ, Quesada AR. The Marine Fungal Metabolite, AD0157, Inhibits Angiogenesis by Targeting the Akt Signaling Pathway. Marine Drugs. 2014; 12(1):279-299.

Chicago/Turabian Style

García-Caballero, Melissa; Cañedo, Librada; Fernández-Medarde, Antonio; Medina, Miguel Á.; Quesada, Ana R. 2014. "The Marine Fungal Metabolite, AD0157, Inhibits Angiogenesis by Targeting the Akt Signaling Pathway." Mar. Drugs 12, no. 1: 279-299.


Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert